title: Selecting the optimal treatment for glucocorticoid-induced osteoporosis.
authors.forename: Florence
authors.initials: F
authors.lastname: Chopin
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Hoppé
authors.forename: Gauthier
authors.initials: G
authors.lastname: Morel
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Biver
authors.forename: Séverine
authors.initials: S
authors.lastname: Borg
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000517:prevention & control; D019587:Dietary Supplements; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D000893:Anti-Inflammatory Agents; D050071:Bone Density Conservation Agents; D005938:Glucocorticoids